Drug intelligence / Profile preview

BB-1710

Development stage: Unknown
Lead developer: Bliss Media
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BB-1710 is an investigational antibody-drug conjugate (ADC) developed by BlissBio (Bliss Biopharmaceutical) for the treatment of solid tumors. The specific target and payload of BB-1710 have not been publicly disclosed as of April 2025. It is part of a pipeline that includes other ADCs with known targets, but for BB-1710, both the molecular target and mechanism remain undisclosed. The drug is currently in clinical development for various solid tumor indications[7].

Beyond the preview

Go deeper on BB-1710.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BB-1710.

Explore the full profile